Roth Capital Research Analysts Lift Earnings Estimates for LeMaitre Vascular, Inc. (NASDAQ:LMAT)

LeMaitre Vascular, Inc. (NASDAQ:LMAT) – Equities researchers at Roth Capital lifted their FY2024 earnings per share estimates for shares of LeMaitre Vascular in a research report issued to clients and investors on Friday, August 2nd. Roth Capital analyst J. Wittes now anticipates that the medical instruments supplier will post earnings of $1.81 per share for the year, up from their prior estimate of $1.77. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for LeMaitre Vascular’s current full-year earnings is $1.77 per share. Roth Capital also issued estimates for LeMaitre Vascular’s Q4 2024 earnings at $0.43 EPS, Q2 2025 earnings at $0.53 EPS, Q3 2025 earnings at $0.49 EPS, FY2025 earnings at $2.03 EPS, FY2026 earnings at $2.28 EPS and FY2027 earnings at $2.50 EPS.

Several other equities analysts have also issued reports on the company. JMP Securities upped their target price on LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a report on Friday, May 3rd. Lake Street Capital initiated coverage on LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective for the company. Barrington Research increased their price objective on LeMaitre Vascular from $79.00 to $92.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, August 2nd. Finally, Roth Mkm reissued a “buy” rating and set a $100.00 price objective on shares of LeMaitre Vascular in a report on Friday, May 31st. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, LeMaitre Vascular has an average rating of “Moderate Buy” and an average price target of $86.50.

LeMaitre Vascular Stock Up 1.8 %

LMAT stock opened at $81.89 on Monday. The firm has a market cap of $1.84 billion, a PE ratio of 54.23, a P/E/G ratio of 2.63 and a beta of 0.89. The business has a 50 day moving average of $82.74 and a 200-day moving average of $72.22. LeMaitre Vascular has a 12-month low of $44.27 and a 12-month high of $91.76.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.05. The company had revenue of $55.85 million during the quarter, compared to analyst estimates of $54.98 million. LeMaitre Vascular had a return on equity of 12.63% and a net margin of 18.33%. LeMaitre Vascular’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.37 earnings per share.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th will be given a dividend of $0.16 per share. The ex-dividend date is Thursday, August 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.78%. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the sale, the chief executive officer now owns 1,958,328 shares in the company, valued at $168,944,956.56. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the sale, the chief executive officer now owns 1,958,328 shares in the company, valued at $168,944,956.56. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bridget A. Ross sold 5,500 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $77.99, for a total value of $428,945.00. Following the sale, the director now owns 2,278 shares in the company, valued at approximately $177,661.22. The disclosure for this sale can be found here. Insiders have sold a total of 45,506 shares of company stock worth $3,877,667 over the last 90 days. Corporate insiders own 10.79% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently made changes to their positions in LMAT. Mesirow Institutional Investment Management Inc. purchased a new stake in shares of LeMaitre Vascular in the fourth quarter worth $8,837,000. F M Investments LLC purchased a new stake in shares of LeMaitre Vascular in the second quarter worth $7,443,000. Congress Asset Management Co. MA raised its position in shares of LeMaitre Vascular by 17.0% in the fourth quarter. Congress Asset Management Co. MA now owns 594,672 shares of the medical instruments supplier’s stock worth $33,754,000 after buying an additional 86,293 shares in the last quarter. Summit Creek Advisors LLC raised its position in shares of LeMaitre Vascular by 37.8% in the fourth quarter. Summit Creek Advisors LLC now owns 228,501 shares of the medical instruments supplier’s stock worth $12,970,000 after buying an additional 62,737 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in shares of LeMaitre Vascular by 554.7% in the first quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after buying an additional 47,218 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.